Shionogi Inc., a U.S. subsidiary of Shionogi & Co., Ltd, announced the appointment of Ramón Polo, MBA, PharmD, Ph.D. as Senior Vice President, Head of Regulatory Affairs.
“Dr. Polo’s extensive regulatory leadership experience is a welcome addition to Shionogi at this pivotal time for the company in the U.S.,” said Nate McCutcheon, President and Chief Executive Officer, Shionogi Inc. “As a leader in infectious disease, our robust clinical development program includes a late-stage investigational oral antiviral for COVID-19 and early-stage antibiotic programs through our acquisition of Qpex. We are also progressing additional key programs in other therapeutic areas with an investigational treatment for Fragile X syndrome in Phase 2b/3 studies and studies underway for acute ischemic stroke, obesity and oncology.”
Dr. Polo’s diverse expertise includes overseeing clinical development operations, pharmacovigilance programs and regulatory strategies. He joins Shionogi Inc. from Johnson & Johnson, where he served as the Vice President, Head of Infectious Diseases, Vaccines & Global Public Health Regulatory Affairs.
“I was initially drawn to Shionogi because of the company’s rich heritage in infectious disease, and as I learned more about the pipeline, recent investments and acquisitions, as well as where Shionogi intends to be by 2030, I realized the significant opportunity ahead to contribute meaningfully across multiple disease states with unmet patient needs,” said Dr. Polo. “It’s an exciting time to join Shionogi and an incredible step in the next stage of my career.”
In his role at Johnson & Johnson, Dr. Polo was responsible for driving regulatory strategy across the U.S., Europe, Asia Pacific and Latin America. Prior to this, Dr. Polo led the development strategy of treatments for influenza, RSV and hepatitis C at Janssen Pharmaceutical Companies of Johnson & Johnson.
Dr. Polo received his PharmD, Master of Science and Ph.D. in Clinical Biochemistry from the Complutense University of Madrid in Spain. He obtained his Global MBA from the IESE Business School, University of Navarra, and attended the Program for Management Development at Harvard Business School.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!